Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Equities research analysts at Oppenheimer decreased their FY2022 earnings per share (EPS) estimates for Portola Pharmaceuticals in a note issued to investors on Thursday, August 8th. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of $0.51 for the year, down from their previous forecast of $0.52. Oppenheimer has a “Buy” rating and a $42.00 price target on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ FY2023 earnings at $2.54 EPS.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. Portola Pharmaceuticals had a negative net margin of 618.46% and a negative return on equity of 238.48%. The firm had revenue of $28.42 million during the quarter, compared to the consensus estimate of $25.42 million. During the same quarter in the previous year, the firm posted ($1.61) EPS. The company’s revenue for the quarter was up 608.7% compared to the same quarter last year.
Several other research analysts also recently weighed in on PTLA. William Blair reaffirmed an “outperform” rating on shares of Portola Pharmaceuticals in a report on Monday, June 17th. BidaskClub raised shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Wednesday, July 17th. ValuEngine downgraded shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Cowen set a $45.00 target price on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $41.88.
Portola Pharmaceuticals stock traded up $0.34 during mid-day trading on Friday, hitting $30.70. The stock had a trading volume of 29,084 shares, compared to its average volume of 847,904. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -6.13 and a beta of 2.18. The company has a debt-to-equity ratio of 5.15, a current ratio of 4.81 and a quick ratio of 4.77. The company has a 50 day moving average of $26.43. Portola Pharmaceuticals has a one year low of $14.81 and a one year high of $37.95.
Hedge funds have recently made changes to their positions in the business. Icon Wealth Partners LLC purchased a new stake in Portola Pharmaceuticals in the 1st quarter worth $26,000. Next Capital Management LLC purchased a new stake in Portola Pharmaceuticals in the 2nd quarter worth $27,000. FTB Advisors Inc. purchased a new stake in Portola Pharmaceuticals in the 1st quarter worth $33,000. Cornerstone Advisors Inc. purchased a new stake in Portola Pharmaceuticals in the 1st quarter worth $46,000. Finally, Valley National Advisers Inc. lifted its stake in Portola Pharmaceuticals by 32.0% in the 2nd quarter. Valley National Advisers Inc. now owns 4,046 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 981 shares in the last quarter.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
See Also: What is meant by a buy rating?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.